# MFSD3

## Overview
MFSD3 is a gene that encodes the protein major facilitator superfamily domain containing 3, which is a member of the major facilitator superfamily (MFS) of transporters. This protein is characterized by its 12 transmembrane helices and is involved in the transport of small solutes across cell membranes. Although the precise function of MFSD3 in human physiology is not fully understood, it is hypothesized to function as a putative acetyl-CoA transporter due to its sequence similarity with SLC33A1, a known acetyl-CoA transporter. This suggests a potential role in lipid metabolism and mitochondrial bioenergetics. The protein's involvement in cellular responses to toxic substances and its regulation through epigenetic modifications further highlight its significance in cellular defense mechanisms and metabolic regulation (Perland2016The; Cardoso2021MultiOmics; Xu2021SLC4A11).

## Structure
MFSD3 is a protein that belongs to the major facilitator superfamily (MFS) and is characterized by a structure comprising 12 transmembrane helices (TMS) (Perland2016The; Perland2017Characteristics). The primary structure of MFSD3 consists of 412 amino acids (Perland2017Characteristics). Sequence alignment shows that MFSD3 shares 19.5% sequence identity with SLC33A1, with 114 identical amino acids, suggesting some evolutionary conservation (Perland2016The).

The secondary structure analysis indicates that MFSD3's transmembrane helices may not all meet the highest probability criterion, indicating some divergence from typical TMS structures (Perland2016The). Tertiary structure modeling suggests that MFSD3 forms a pore, potentially facilitating substrate transport, with both N- and C-terminals located in the cytoplasm (Perland2016The). The homology model of MFSD3, based on the YajR MFS transporter, supports its classification as an MFS transporter, with a cylindrical structure through which substrates could be transported (Perland2016The).

No specific information is available regarding the quaternary structure, post-translational modifications, or splice variant isoforms of MFSD3 in the provided context.

## Function
The MFSD3 gene encodes a protein that is part of the major facilitator superfamily, which is involved in the transport of small solutes across cell membranes. Although the precise biological function of MFSD3 in healthy human cells remains unclear, it is suggested to be a putative acetyl-CoA transporter due to its sequence similarity with SLC33A1, a known acetyl-CoA transporter. SLC33A1 plays a crucial role in maintaining intracellular acetyl-CoA homeostasis within the endoplasmic reticulum and acts as a metabolic regulator, influencing lipid metabolism and mitochondrial bioenergetics (Cardoso2021MultiOmics).

MFSD3 shares the 'Acatn' (Acetyl-coenzyme A transporter 1) Pfam domain with SLC33A1, although with a low sequence identity of 18.2%, indicating a potential functional relationship (Gyimesi2022Systematic). The gene has been associated with fatty acid metabolism, as polymorphisms in MFSD3 have been linked to variations in saturated and monosaturated fatty acid composition in cow milk, suggesting a role in lipid metabolism (Cardoso2021MultiOmics). Despite these associations, further studies are needed to elucidate the specific molecular processes and cellular roles of MFSD3 in human physiology.

## Clinical Significance
Alterations in the expression of the MFSD3 gene have been linked to cellular responses to toxic substances, such as deoxynivalenol (DON), a mycotoxin that can contaminate food supplies. In studies involving porcine intestinal epithelial cells (IPEC-J2), exposure to DON significantly decreased the expression levels of MFSD3, which is associated with reduced cell viability and increased apoptosis. This suggests that MFSD3 may play a role in cellular defense mechanisms against DON-induced cytotoxicity, potentially through pathways involving oxidative stress and apoptosis (Xu2021SLC4A11).

The methylation status of the MFSD3 gene also appears to influence its expression. Increased methylation at specific CpG sites within the gene's promoter region correlates with decreased mRNA expression, indicating that epigenetic modifications may suppress MFSD3 expression. This suppression could impact the gene's ability to maintain cell viability under toxic conditions (Xu2021SLC4A11).

Misannotation of MFSD3 variants in genetic studies can lead to challenges in clinical interpretation, as seen in hereditary cancer diagnostics. Such misannotations could potentially affect the understanding of MFSD3's role in disease contexts (Kalfakakou2021Pitfalls). However, the full clinical significance of MFSD3 mutations and expression alterations remains under investigation.


## References


[1. (Cardoso2021MultiOmics) Tainã Figueiredo Cardoso, Luiz Lehmann Coutinho, Jennifer Jessica Bruscadin, Wellison Jarles da Silva Diniz, Juliana Petrini, Bruno Gabriel Nascimento Andrade, Priscila Silva Neubern de Oliveira, Mirele Daiana Poleti, Aline Silva Mello Cesar, Juliano Coelho da Silveira, Marcos Roberto Chiaratti, Adhemar Zerlotini, Gerson Barreto Mourão, and Luciana Correia de Almeida Regitano. Multi-omics approach reveals mir-snps affecting muscle fatty acids profile in nelore cattle. Genes, 12(1):67, January 2021. URL: http://dx.doi.org/10.3390/genes12010067, doi:10.3390/genes12010067. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes12010067)

[2. (Perland2016The) Emelie Perland, Sofie V. Hellsten, Emilia Lekholm, Mikaela M. Eriksson, Vasiliki Arapi, and Robert Fredriksson. The novel membrane-bound proteins mfsd1 and mfsd3 are putative slc transporters affected by altered nutrient intake. Journal of Molecular Neuroscience, 61(2):199–214, December 2016. URL: http://dx.doi.org/10.1007/s12031-016-0867-8, doi:10.1007/s12031-016-0867-8. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12031-016-0867-8)

[3. (Perland2017Characteristics) Emelie Perland, Sonchita Bagchi, Axel Klaesson, and Robert Fredriksson. Characteristics of 29 novel atypical solute carriers of major facilitator superfamily type: evolutionary conservation, predicted structure and neuronal co-expression. Open Biology, 7(9):170142, September 2017. URL: http://dx.doi.org/10.1098/rsob.170142, doi:10.1098/rsob.170142. This article has 42 citations and is from a peer-reviewed journal.](https://doi.org/10.1098/rsob.170142)

[4. (Kalfakakou2021Pitfalls) Despoina Kalfakakou, Irene Konstantopoulou, Drakoulis Yannoukakos, and Florentia Fostira. Pitfalls in variant annotation for hereditary cancer diagnostics: the example of illumina® variantstudio®. Genomics, 113(1):748–754, January 2021. URL: http://dx.doi.org/10.1016/j.ygeno.2020.10.005, doi:10.1016/j.ygeno.2020.10.005. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ygeno.2020.10.005)

[5. (Gyimesi2022Systematic) Gergely Gyimesi and Matthias A. Hediger. Systematic in silico discovery of novel solute carrier-like proteins from proteomes. PLOS ONE, 17(7):e0271062, July 2022. URL: http://dx.doi.org/10.1371/journal.pone.0271062, doi:10.1371/journal.pone.0271062. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0271062)

[6. (Xu2021SLC4A11) Yafei Xu, Xiaolei Chen, Luchen Yu, Yi Wang, Haifei Wang, Zhengchang Wu, Shenglong Wu, and Wenbin Bao. Slc4a11 and mfsd3 gene expression changes in deoxynivalenol treated ipec-j2 cells. Frontiers in Genetics, July 2021. URL: http://dx.doi.org/10.3389/fgene.2021.697883, doi:10.3389/fgene.2021.697883. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2021.697883)